These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 25351552

  • 21. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F.
    Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
    [Abstract] [Full Text] [Related]

  • 22. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
    Glaeser M, Niederacher D, Djahansouzi S, Hanstein B, Dittrich R, Beckmann MW, Fasching PA, Ackermann S.
    Anticancer Res; 2006 Oct; 26(1B):735-44. PubMed ID: 16739346
    [Abstract] [Full Text] [Related]

  • 23. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
    Kallio A, Guo T, Lamminen E, Seppänen J, Kangas L, Väänänen HK, Härkönen P.
    Mol Cell Endocrinol; 2008 Jul 16; 289(1-2):38-48. PubMed ID: 18455292
    [Abstract] [Full Text] [Related]

  • 24. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
    Borri P, Coronnello M, Noci I, Pesciullesi A, Peri A, Caligiani R, Maggi M, Torricelli F, Scarselli G, Chieffi O, Mazzei T, Mini E.
    Gynecol Oncol; 1998 Dec 16; 71(3):396-403. PubMed ID: 9887238
    [Abstract] [Full Text] [Related]

  • 25. [Overexpression of estrogen receptor-related receptor alpha can stimulate estrogen receptor negative endometrial cancer cell proliferation].
    Sun PM, Wei LH, Gao M, Wang JL, Zhao LJ, Wang DP, Zhang JX.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jun 16; 42(6):408-11. PubMed ID: 17697604
    [Abstract] [Full Text] [Related]

  • 26. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.
    Taylor CM, Blanchard B, Zava DT.
    Cancer Res; 1984 Apr 16; 44(4):1409-14. PubMed ID: 6704959
    [Abstract] [Full Text] [Related]

  • 27. [Impact of calcium channel antagonists for estrogen action on the endometrial carcinoma HEC-1A cells].
    Bao XX, Wang JL, Wei LH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Mar 16; 47(3):212-7. PubMed ID: 22781074
    [Abstract] [Full Text] [Related]

  • 28. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C, Gajdos C, Cheng D, Jordan VC.
    J Steroid Biochem Mol Biol; 2005 Feb 16; 93(2-5):249-56. PubMed ID: 15860267
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells.
    Klinge CM, Jernigan SC, Risinger KE.
    Endocrinology; 2002 Mar 16; 143(3):853-67. PubMed ID: 11861507
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    Obrero M, Yu DV, Shapiro DJ.
    J Biol Chem; 2002 Nov 22; 277(47):45695-703. PubMed ID: 12244117
    [Abstract] [Full Text] [Related]

  • 35. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.
    Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, Diaz-Arrastia CR, Salama SA.
    J Steroid Biochem Mol Biol; 2011 Sep 22; 126(3-5):78-86. PubMed ID: 21600284
    [Abstract] [Full Text] [Related]

  • 36. Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro.
    Park DW, Ryu HS, Choi DS, Park YH, Chang KH, Min CK.
    Gynecol Oncol; 2001 Sep 22; 82(3):442-9. PubMed ID: 11520138
    [Abstract] [Full Text] [Related]

  • 37. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC.
    Clin Cancer Res; 2002 Jun 22; 8(6):1995-2001. PubMed ID: 12060645
    [Abstract] [Full Text] [Related]

  • 38. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.
    Cancer Res; 1999 Aug 01; 59(15):3646-51. PubMed ID: 10446976
    [Abstract] [Full Text] [Related]

  • 39. Involvement of caspase-9 but not caspase-8 in the anti-apoptotic effects of estradiol and 4-OH-Estradiol in MCF-7 human breast cancer cells.
    Gregoraszczuk E, Ptak A.
    Endocr Regul; 2011 Jan 01; 45(1):3-8. PubMed ID: 21314204
    [Abstract] [Full Text] [Related]

  • 40. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells.
    Bhat KP, Pezzuto JM.
    Cancer Res; 2001 Aug 15; 61(16):6137-44. PubMed ID: 11507064
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.